ProLynx

San Francisco, United States

ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.

$70.0M raised

Dec 2025

Series A

Top Investors

OrbiMedNational Science Foundation5AM VenturesNational Institutes of HealthMonograph Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ProLynx raised?

ProLynx has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.

Who are ProLynx's investors?

ProLynx's investors include OrbiMed, National Science Foundation, 5AM Ventures, National Institutes of Health, Monograph Capital.

Where is ProLynx headquartered?

ProLynx is headquartered in San Francisco, United States.

What does ProLynx do?

ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.

What stage is ProLynx at?

ProLynx is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 11, 2025.

MLA

"ProLynx — Funding & Investors." VCBacked, December 11, 2025, https://www.vcbacked.co/company/prolynx. Accessed June 4, 2026.

APA

VCBacked. (2025). ProLynx — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/prolynx

Wikipedia (cite web)

{{cite web |title=ProLynx — Funding & Investors |url=https://www.vcbacked.co/company/prolynx |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 11, 2025.